Verapamil P-glycoprotein transport across the rat blood-brain barrier: Cyclosporine, a concentration inhibition analysis, and comparison with human data

Peng Hsiao, Lucy Sasongko, Jeanne Link, David A. Mankoff, Mark Muzi, Ann C. Collier, Jashvant D. Unadkat

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

To predict the magnitude of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier (BBB), rodent studies are routinely conducted where P-gp is chemically inhibited. For such studies to be predictive of interactions at the human BBB, the plasma concentration of the P-gp inhibitor must be comparable with that observed in the clinic. Therefore, we determined the in vivo EC50 of P-gp inhibition at the rat BBB using verapamil as a model P-gp substrate and cyclosporine A (CsA) as the model P-gp inhibitor. Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to ∼12 μM. Then, an i.v. tracer dose of [3H]verapamil was administered, and 20 min after verapamil administration, the animals were sacrificed for determination of blood, plasma, and brain 3H radioactivity by scintillation counting. The percentage increase in the brain/blood 3H radioactivity (relative to 0 μM CsA) was described by the Hill equation with Emax, 1290%; EC50, 7.2 μM; and γ, 3.8. Previously, using [11C]verapamil, we have shown that the human brain/blood 11C radioactivity was increased by 79% at 2.8 μM CsA blood concentration. At an equivalent CsA blood concentration, the rat brain/blood 3H radioactivity was increased by a remarkably similar extent of 75%. This is the first time that an in vivo CsA EC50 of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition was compared between the rat and the human BBB at the same blood CsA concentration.

Original languageEnglish (US)
Pages (from-to)704-710
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume317
Issue number2
DOIs
StatePublished - May 2006
Externally publishedYes

Fingerprint

P-Glycoprotein
Verapamil
Blood-Brain Barrier
Cyclosporine
Radioactivity
Brain
Scintillation Counting
Isoflurane
Drug Interactions
Sprague Dawley Rats
Rodentia
Anesthesia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Verapamil P-glycoprotein transport across the rat blood-brain barrier : Cyclosporine, a concentration inhibition analysis, and comparison with human data. / Hsiao, Peng; Sasongko, Lucy; Link, Jeanne; Mankoff, David A.; Muzi, Mark; Collier, Ann C.; Unadkat, Jashvant D.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 317, No. 2, 05.2006, p. 704-710.

Research output: Contribution to journalArticle

Hsiao, Peng ; Sasongko, Lucy ; Link, Jeanne ; Mankoff, David A. ; Muzi, Mark ; Collier, Ann C. ; Unadkat, Jashvant D. / Verapamil P-glycoprotein transport across the rat blood-brain barrier : Cyclosporine, a concentration inhibition analysis, and comparison with human data. In: Journal of Pharmacology and Experimental Therapeutics. 2006 ; Vol. 317, No. 2. pp. 704-710.
@article{e706080c7ac14448b0bf64fb42f91dea,
title = "Verapamil P-glycoprotein transport across the rat blood-brain barrier: Cyclosporine, a concentration inhibition analysis, and comparison with human data",
abstract = "To predict the magnitude of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier (BBB), rodent studies are routinely conducted where P-gp is chemically inhibited. For such studies to be predictive of interactions at the human BBB, the plasma concentration of the P-gp inhibitor must be comparable with that observed in the clinic. Therefore, we determined the in vivo EC50 of P-gp inhibition at the rat BBB using verapamil as a model P-gp substrate and cyclosporine A (CsA) as the model P-gp inhibitor. Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to ∼12 μM. Then, an i.v. tracer dose of [3H]verapamil was administered, and 20 min after verapamil administration, the animals were sacrificed for determination of blood, plasma, and brain 3H radioactivity by scintillation counting. The percentage increase in the brain/blood 3H radioactivity (relative to 0 μM CsA) was described by the Hill equation with Emax, 1290{\%}; EC50, 7.2 μM; and γ, 3.8. Previously, using [11C]verapamil, we have shown that the human brain/blood 11C radioactivity was increased by 79{\%} at 2.8 μM CsA blood concentration. At an equivalent CsA blood concentration, the rat brain/blood 3H radioactivity was increased by a remarkably similar extent of 75{\%}. This is the first time that an in vivo CsA EC50 of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition was compared between the rat and the human BBB at the same blood CsA concentration.",
author = "Peng Hsiao and Lucy Sasongko and Jeanne Link and Mankoff, {David A.} and Mark Muzi and Collier, {Ann C.} and Unadkat, {Jashvant D.}",
year = "2006",
month = "5",
doi = "10.1124/jpet.105.097931",
language = "English (US)",
volume = "317",
pages = "704--710",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Verapamil P-glycoprotein transport across the rat blood-brain barrier

T2 - Cyclosporine, a concentration inhibition analysis, and comparison with human data

AU - Hsiao, Peng

AU - Sasongko, Lucy

AU - Link, Jeanne

AU - Mankoff, David A.

AU - Muzi, Mark

AU - Collier, Ann C.

AU - Unadkat, Jashvant D.

PY - 2006/5

Y1 - 2006/5

N2 - To predict the magnitude of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier (BBB), rodent studies are routinely conducted where P-gp is chemically inhibited. For such studies to be predictive of interactions at the human BBB, the plasma concentration of the P-gp inhibitor must be comparable with that observed in the clinic. Therefore, we determined the in vivo EC50 of P-gp inhibition at the rat BBB using verapamil as a model P-gp substrate and cyclosporine A (CsA) as the model P-gp inhibitor. Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to ∼12 μM. Then, an i.v. tracer dose of [3H]verapamil was administered, and 20 min after verapamil administration, the animals were sacrificed for determination of blood, plasma, and brain 3H radioactivity by scintillation counting. The percentage increase in the brain/blood 3H radioactivity (relative to 0 μM CsA) was described by the Hill equation with Emax, 1290%; EC50, 7.2 μM; and γ, 3.8. Previously, using [11C]verapamil, we have shown that the human brain/blood 11C radioactivity was increased by 79% at 2.8 μM CsA blood concentration. At an equivalent CsA blood concentration, the rat brain/blood 3H radioactivity was increased by a remarkably similar extent of 75%. This is the first time that an in vivo CsA EC50 of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition was compared between the rat and the human BBB at the same blood CsA concentration.

AB - To predict the magnitude of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier (BBB), rodent studies are routinely conducted where P-gp is chemically inhibited. For such studies to be predictive of interactions at the human BBB, the plasma concentration of the P-gp inhibitor must be comparable with that observed in the clinic. Therefore, we determined the in vivo EC50 of P-gp inhibition at the rat BBB using verapamil as a model P-gp substrate and cyclosporine A (CsA) as the model P-gp inhibitor. Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to ∼12 μM. Then, an i.v. tracer dose of [3H]verapamil was administered, and 20 min after verapamil administration, the animals were sacrificed for determination of blood, plasma, and brain 3H radioactivity by scintillation counting. The percentage increase in the brain/blood 3H radioactivity (relative to 0 μM CsA) was described by the Hill equation with Emax, 1290%; EC50, 7.2 μM; and γ, 3.8. Previously, using [11C]verapamil, we have shown that the human brain/blood 11C radioactivity was increased by 79% at 2.8 μM CsA blood concentration. At an equivalent CsA blood concentration, the rat brain/blood 3H radioactivity was increased by a remarkably similar extent of 75%. This is the first time that an in vivo CsA EC50 of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition was compared between the rat and the human BBB at the same blood CsA concentration.

UR - http://www.scopus.com/inward/record.url?scp=33645881089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645881089&partnerID=8YFLogxK

U2 - 10.1124/jpet.105.097931

DO - 10.1124/jpet.105.097931

M3 - Article

C2 - 16415090

AN - SCOPUS:33645881089

VL - 317

SP - 704

EP - 710

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -